Natco Pharma Limited, founded in Hyderabad in 1981 with an initial investment of INR 3.3 million, has evolved from a single-unit operation with just 20 employees into a major player in the pharmaceutical industry. Today, Natco boasts eight manufacturing facilities across India, equipped with state-of-the-art research laboratories and advanced capabilities in new drug development.
The company, which now employs around 4,500 people, is consistently ranked among the fastest-growing pharmaceutical companies in India. Natco is renowned for its innovative approach to pharmaceutical research and development, underscoring its commitment to advancing healthcare solutions and maintaining its competitive edge in the global market.
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | |
| Promoters + | 48.84% | 49.76% | 49.71% | 49.71% | 49.71% |
| FIIs + | 11.91% | 11.03% | 12.82% | 13.72% | 16.14% |
| DIIs + | 15.38% | 15.15% | 14.01% | 11.26% | 9.69% |
| Public + | 23.87% | 24.08% | 23.48% | 25.32% | 24.46% |
| No. of Shareholders | 1,53,663 | 1,55,181 | 1,63,753 | 2,07,571 | 2,28,467 |
The shareholding patterns of Natco Pharma Limited from March 2023 to March 2024 reveal notable shifts among different investor groups. Promoters increased their stake from 48.84% in March 2023 to 49.76% by June 2023, maintaining it at 49.71% thereafter, demonstrating steady confidence. Foreign Institutional Investors (FIIs) significantly raised their holdings from 11.91% to 16.14%, reflecting growing foreign interest. Conversely, Domestic Institutional Investors (DIIs) reduced their stake from 15.38% to 9.69%, indicating a strategic shift. Public shareholding remained relatively stable, fluctuating slightly from 23.87% to 24.46%. The number of shareholders surged from 153,663 to 228,467, underscoring increasing investor interest and confidence in Natco Pharma.
Natco Pharma Reports 59% Profit Surge in Q1 FY25, Driven by Strong Revenue Growth and Export Success
- Profit Increase: Natco Pharma Ltd. achieved a significant profit rise of 59.05% year-on-year, amounting to ₹668.5 crore.
- Revenue Growth: The company’s revenue from operations increased by 19.47% year-on-year, totaling ₹1,362.6 crore for the quarter.
- Export Success: The revenue growth was largely attributed to the export formulations segment, which experienced a substantial 36.86% year-on-year increase.
- Interim Dividend: An interim dividend of ₹3 per equity share was declared, with the record date set for August 23, 2024.
- Quarterly Performance: The strong performance reflects the company’s ongoing strategic focus on expanding its global footprint and enhancing product offerings.
- Operational Efficiency: Natco Pharma’s improved financial results highlight its effective operational strategies and cost management practices.
- Market Expansion: The notable growth in export formulations underscores the company’s successful penetration into international markets.
- Future Outlook: The positive financial results and interim dividend declaration suggest a robust financial health and confidence in continued growth.
Below are the trading platforms that you can use to purchase Natco Pharma Limited’s shares:
- Zerodha
- Upstox
- Groww
- AngelOne
- ICICIDirect
| When | Maximum Price | Minimum Price |
| August 2024 | 1,474.15 | 1,281.87 |
| September 2024 | 1,533.12 | 1,333.15 |
| October 2024 | 1,503.06 | 1,307.01 |
| November 2024 | 1,563.18 | 1,359.29 |
| December 2024 | 1,578.81 | 1,372.88 |
In August 2024, the maximum price of Natco Pharma is projected to reach ₹1,474.15, while the minimum price is expected to be ₹1,281.87. Moving forward, by September 2024, the maximum price of Natco Pharma is anticipated to rise to ₹1,533.12, with a minimum price of ₹1,333.15. In October 2024, Natco Pharma’s maximum price is forecasted to touch ₹1,503.06, while the minimum is expected to hover around ₹1,307.01. By November 2024, the maximum price is projected to increase further to ₹1,563.18, with a minimum of ₹1,359.29. Finally, as we step into December 2024, the maximum price of Natco Pharma is expected to reach ₹1,578.81, while the minimum price is anticipated to be ₹1,372.88.
| When | Maximum Price | Minimum Price |
| January 2025 | 1,594.60 | 1,226.62 |
| February 2025 | 1,610.71 | 1,239.01 |
| March 2025 | 1,644.53 | 1,265.03 |
| April 2025 | 1,628.25 | 1,252.50 |
| May 2025 | 1,580.83 | 1,216.02 |
| June 2025 | 1,651.96 | 1,270.74 |
| July 2025 | 1,619.57 | 1,245.82 |
| August 2025 | 1,669.66 | 1,284.36 |
| September 2025 | 1,689.70 | 1,299.77 |
| October 2025 | 1,733.63 | 1,333.56 |
| November 2025 | 1,776.97 | 1,366.90 |
| December 2025 | 1,856.93 | 1,428.41 |
As we step into January 2025, Natco Pharma’s price is expected to range between ₹1,594.60 and ₹1,226.62. By February, prices may reach a maximum of ₹1,610.71 and a minimum of ₹1,239.01. In March, the price could range from ₹1,644.53 to ₹1,265.03. April may see prices between ₹1,628.25 and ₹1,252.50, while May could fluctuate from ₹1,580.83 to ₹1,216.02. As we approach June, prices may reach ₹1,651.96 and ₹1,270.74. July could see a range of ₹1,619.57 to ₹1,245.82, and August may hit ₹1,669.66 to ₹1,284.36. In September, prices might be between ₹1,689.70 and ₹1,299.77. October could range from ₹1,733.63 to ₹1,333.56, and November from ₹1,776.97 to ₹1,366.90. Finally, December 2025 could see prices between ₹1,856.93 and ₹1,428.41.
| When | Maximum Price | Minimum Price |
| January 2026 | 1,912.64 | 1,471.26 |
| February 2026 | 1,864.83 | 1,434.48 |
| March 2026 | 1,902.12 | 1,463.17 |
| April 2026 | 1,940.94 | 1,493.03 |
| May 2026 | 1,921.72 | 1,478.25 |
| June 2026 | 1,969.77 | 1,515.21 |
| July 2026 | 1,931.14 | 1,485.50 |
| August 2026 | 1,990.87 | 1,531.44 |
| September 2026 | 2,030.69 | 1,562.07 |
| October 2026 | 2,083.49 | 1,602.68 |
| November 2026 | 2,135.57 | 1,642.75 |
| December 2026 | 2,188.96 | 1,683.82 |
| When | Maximum Price | Minimum Price |
| January 2027 | 2,210.85 | 1,700.66 |
| February 2027 | 2,267.54 | 1,744.26 |
| March 2027 | 2,355.97 | 1,812.29 |
| April 2027 | 2,309.78 | 1,776.75 |
| May 2027 | 2,242.50 | 1,725.00 |
| June 2027 | 2,343.42 | 1,802.63 |
| July 2027 | 2,297.47 | 1,767.28 |
| August 2027 | 2,368.52 | 1,821.94 |
| September 2027 | 2,451.42 | 1,885.71 |
| October 2027 | 2,515.16 | 1,934.74 |
| November 2027 | 2,578.04 | 1,983.11 |
| December 2027 | 2,642.49 | 2,032.68 |
| When | Maximum Price | Minimum Price |
| January 2028 | 2,695.34 | 2,073.34 |
| February 2028 | 2,764.45 | 2,126.50 |
| March 2028 | 2,872.26 | 2,209.43 |
| April 2028 | 2,815.94 | 2,166.11 |
| May 2028 | 2,733.93 | 2,103.02 |
| June 2028 | 2,856.95 | 2,197.66 |
| July 2028 | 2,800.93 | 2,154.56 |
| August 2028 | 2,887.56 | 2,221.20 |
| September 2028 | 2,988.63 | 2,298.94 |
| October 2028 | 3,066.33 | 2,358.71 |
| November 2028 | 3,142.99 | 2,417.68 |
| December 2028 | 3,221.56 | 2,478.12 |
| When | Maximum Price | Minimum Price |
| January 2029 | 3,285.99 | 2,527.69 |
| February 2029 | 3,370.25 | 2,592.50 |
| March 2029 | 3,501.69 | 2,693.61 |
| April 2029 | 3,433.03 | 2,640.79 |
| May 2029 | 3,333.04 | 2,563.88 |
| June 2029 | 3,483.02 | 2,679.25 |
| July 2029 | 3,414.73 | 2,626.72 |
| August 2029 | 3,520.34 | 2,707.95 |
| September 2029 | 3,643.55 | 2,802.73 |
| October 2029 | 3,738.28 | 2,875.60 |
| November 2029 | 3,831.74 | 2,947.49 |
| December 2029 | 3,927.53 | 3,021.18 |
| When | Maximum Price | Minimum Price |
| January 2030 | 4,006.09 | 3,081.60 |
| February 2030 | 4,108.81 | 3,160.62 |
| March 2030 | 4,269.05 | 3,283.88 |
| April 2030 | 4,185.34 | 3,219.49 |
| May 2030 | 4,063.44 | 3,125.72 |
| June 2030 | 4,246.29 | 3,266.38 |
| July 2030 | 4,163.03 | 3,202.33 |
| August 2030 | 4,291.79 | 3,301.37 |
| September 2030 | 4,442.00 | 3,416.92 |
| October 2030 | 4,557.49 | 3,505.76 |
| November 2030 | 4,671.43 | 3,593.41 |
| December 2030 | 4,788.21 | 3,683.24 |
In 2030, Natco Pharma is expected to see significant price variations throughout the year. As we step into January, the maximum price could reach ₹4,006.09, with a minimum of ₹3,081.60. By August, the maximum might rise to ₹4,291.79, while the minimum could be around ₹3,301.37. As we approach December, the maximum price could reach ₹4,788.21, with a minimum of ₹3,683.24.
Financial Condition of Natco Pharma: Last 5 years
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
| Sales + | 1,915 | 2,052 | 1,945 | 2,707 | 3,999 |
| Expenses + | 1,332 | 1,446 | 1,681 | 1,772 | 2,247 |
| Operating Profit | 583 | 606 | 264 | 936 | 1,751 |
| OPM % | 30% | 30% | 14% | 35% | 44% |
| Other Income + | 107 | 104 | 99 | 105 | 128 |
| Interest | 22 | 13 | 18 | 14 | 19 |
| Depreciation | 100 | 117 | 143 | 164 | 187 |
| Profit before tax | 569 | 580 | 202 | 862 | 1,674 |
| Tax % | 19% | 24% | 16% | 17% | 17% |
| Net Profit + | 458 | 442 | 170 | 715 | 1,388 |
| EPS in Rs | 25.31 | 24.18 | 9.31 | 39.18 | 77.51 |
| Dividend Payout % | 27% | 22% | 48% | 14% | 12% |
- Sales Growth: Natco Pharma witnessed a substantial increase in sales from March 2020 to March 2024, rising from ₹1,915 crore to ₹3,999 crore, indicating robust revenue growth over the period.
- Operating Profit: The company’s operating profit showed significant fluctuations, starting at ₹583 crore in March 2020, dipping to ₹264 crore in March 2022, and then rebounding to ₹1,751 crore in March 2024, showcasing volatility in operational performance.
- Operating Profit Margin (OPM): Despite fluctuations, the OPM percentage improved from 30% in March 2020 to 44% in March 2024, reflecting enhanced operational efficiency and profitability.
- Net Profit: Net profit surged from ₹458 crore in March 2020 to ₹1,388 crore in March 2024, indicating substantial growth and profitability enhancement initiatives undertaken by the company.
- Earnings Per Share (EPS): The EPS exhibited significant growth, climbing from ₹25.31 in March 2020 to ₹77.51 in March 2024, reflecting improved profitability and enhanced shareholder value.
- Dividend Payout: The dividend payout percentage fluctuated over the years, from 27% in March 2020 to 12% in March 2024, showcasing variations in the company’s dividend distribution policy.
FAQS
What is the current valuation of Natco Pharma in the stock market?
Natco Pharma’s current market capitalization is an impressive ₹26,185 Crores.
As of August 18th, 2024, the current share price of Natco Pharma is ₹1,462.
According to our analysis, Natco Pharma could reach a maximum of ₹1,856.93 by the end of 2025.
The share price target for Natco Pharma in 2030 is projected to range between ₹3,081.60 and ₹4,788.21.
ALSO READ:
- Ashok Leyland Share Price Target 2024, 2025 to 2030
- UNITED SPIRITS SHARE PRICE TARGET 2024, 2025, 2026, 2027 to 2030
- Nazara Technologies Share Price Target 2024, 2025 to 2030
Conclusion
In conclusion, Natco Pharma Limited has shown remarkable growth and resilience over the years, both in terms of financial performance and market positioning. The company’s significant increase in revenue and profit, driven by strong export growth, reflects its strategic focus on innovation and global market expansion. The shareholding patterns highlight increased confidence from foreign investors, while the number of shareholders continues to rise, indicating growing investor interest. With its robust financial health and steady operational efficiency, Natco Pharma is well-positioned for sustained growth, as reflected in its promising share price projections from 2024 through 2030.
What did we learn?
- 1 Shareholding Patterns
- 2 Natco Pharma Reports 59% Profit Surge in Q1 FY25, Driven by Strong Revenue Growth and Export Success
- 3 How to purchase Natco Pharma Limited’s shares?
- 4 Natco Pharma Limited’s Share Price Prediction: 2024, 2025 to 2030
- 5 Financial Condition of Natco Pharma: Last 5 years
- 6 FAQS
- 7 Conclusion
